Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: A meta-analysis

Chinese Medical Journal

Volumn 126, Issue 9, 2013, Pages 1750-1754

  Zhang, Yong ^a   Tang, Hai Qin ^a   Li, Jin ^a   Fu, Zhao Xin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Dual antiplatelet therapy; Meta analysis; Percutaneous coronary intervention; Triple antiplatelet therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; PLACEBO;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DEATH; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EVALUATION; FOLLOW UP; HEART DEATH; HEART DISEASE; HUMAN; LOADING DRUG DOSE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; SIDE EFFECT; STENT THROMBOSIS;

ASPIRIN; DRUG THERAPY, COMBINATION; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PUBLICATION BIAS; STENTS; TETRAZOLES; TICLOPIDINE;

EID: 84876951160     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122839     Document Type: Article

References (22)

1. Gurbel PA, Tantry US. Aspirin and dopidogrel resistance: consideration and management. J Interv Cardiol 2006; 19: 439-448.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. The clopidogrel in unstable angina to prevent recurrent events trial investigator. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
3. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Coronary stent restenosis in patients treated with cilostazo1. Circulation 2005; 112: 2826-2832.
4. Shen J, Jin HG, Liu ZJ, Wang WQ, Yang Wei, Wang DY, et al. Long-term effect of triple antiplatelet therapy for treatment of patients with diabetes and acute coronary syndrome after drug-eluting stent implantation. Shanghai Med J (Chin) 2010; 33: 566-569.
5. Lu YL, Chen YD, Lü SZ. Effects of intensive antiplatele therapy in patient with high platelet agreeability after percutaneons coronary intervention, Chin J Diabetes (Chin) 2007; 15: 35-37.
6. Zang HY, Han YL, Li Y, Deng J, Jing QM, Wang SL, et al. Long-term effect of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention. Med J Chin PLA (Chin) 2008; 8: 931-934.
7. Chen YD, Lu YL, Jin ZN, Yuan F, Lü SZ. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J 2006; 119: 360-366.
8. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 2011; 26: 502-510.
9. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. JACC Cardiovasc interv 2011; 57: 1264-1270.
10. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-289.
11. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and-LONG trials). Am J Cardiol 2010; 105: 168-173.
12. Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. Am Heart J 2009; 157: 733-739.
13. Lu YL, Chen YD, Lv SZ, Pan WQ, Liu X. Effect of cilostazol on restenosis in elderly patients with coronary bare-metal stents implantation. Chin J Geriatr (Chin) 2006; 25: 537-578.
14. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
15. Han YL, Su QF, Li Y, Kang J, Yan CH, Wang SL. The effects of post coronary stenting triple antiplatelet therapies on platelet functions. Chin J Int Med (Chin) 2006; 45: 635-638.
16. Sun FC, Deng KB. Antiplatelet therapy in patients post percutaneous coronary stent implantion. Chin J Cardiovasc Med (Chin) 2003; 8: 369-371.
17. Takagi H, Umemoto T. Benefit, rather than safety of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials. Int J Cardiol 2011; 153: 74-76.
18. Takagi H, Umemoto T. A meta-analysis of randomized trials of triple versus dual antiplatelet therapy after stent-based percutaneous coronary intervention. Int J Cardiol 2011; 150: 228-230.
19. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-1837.
20. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 576S-599S.
21. Han YL. Individual therapy-Switch the direction of the anti-thrombosis treatment in coronary heart disease. Med J Chin PLA (Chin) 2008; 33: 921-922.
22. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538.